ESSA Pharma's EPI-7386 Monotherapy / Combo Therapy Show Early Activity Against Prostate Cancer

  • ESSA Pharma Inc EPIX presented clinical results from the Phase 1a dose-escalation study of EPI-7386 as a monotherapy for metastatic castration-resistant prostate cancer (mCRPC) resistant to current standard-of-care therapies. 
  • The initial data from 36 patients demonstrate that EPI-7386 was well-tolerated, exhibited a favorable pharmacokinetic profile, and demonstrated initial anti-tumor activity in a heavily pretreated group of patients. 
  • In five patients with measurable disease who were on therapy for more than 12 weeks, tumor volume decreased in all five patients.
  • PSA decreases or PSA stabilization was observed in a clinical subset of patients with no visceral disease and fewer DNA genomic aberrations in non-AR oncogenic pathways.
  • In 17 patients with measurable ctDNA levels at baseline, ctDNA declines were observed in patients harboring AR point mutations, AR gain/amplification, and AR truncations, suggesting EPI-7386's potential activity against these tumors.
  • The company expects to initiate the Phase 1b monotherapy expansion study in Q3 2022 and will plan to enroll two dose cohorts into this study following recent guidance from the FDA from Project Optimus. 
  • In addition to these studies, EPI-7386 is under evaluation in earlier lines of therapy in Phase 1/2 trials combining EPI-7386 with approved second-generation antiandrogens. 
  • Price Action: EPIX shares closed 3.02% at $4.10 during after-hours trading on Monday.

Posted In: BriefsBiotechNewsPenny StocksHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.